Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules …
The immune checkpoint cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is an
inhibitory regulator of T-cell mediated responses that has been investigated as target of …
inhibitory regulator of T-cell mediated responses that has been investigated as target of …
[HTML][HTML] Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis
NA Bosma, MT Warkentin, CL Gan, S Karim… - European urology open …, 2022 - Elsevier
Context Considerable advances have been made in the first-line treatment of metastatic
renal cell carcinoma (mRCC), with immunotherapy-based combinations including …
renal cell carcinoma (mRCC), with immunotherapy-based combinations including …
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open …
Background In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib
showed superior progression-free survival, overall survival, and objective response over …
showed superior progression-free survival, overall survival, and objective response over …
Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study
Background Nivolumab showed an overall survival (OS) benefit in pretreated metastatic
renal cell carcinoma (mRCC). The role of stereotactic body radiotherapy (SBRT) in mRCC …
renal cell carcinoma (mRCC). The role of stereotactic body radiotherapy (SBRT) in mRCC …
[HTML][HTML] Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?
M Catalano, G Procopio, P Sepe, M Santoni… - Pharmacology & …, 2023 - Elsevier
Over the past decade, the management of metastatic renal cell carcinoma (RCC) has
undergone rapid evolution, culminating in a significant improvement in prognosis with …
undergone rapid evolution, culminating in a significant improvement in prognosis with …
New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis
P Lombardi, M Filetti, R Falcone, R Di Bidino… - Cancer Treatment …, 2022 - Elsevier
Several first-line immune-checkpoints inhibitors (ICI) based combinations have been studied
in metastatic renal cell carcinoma (mRCC) without any direct comparison between the …
in metastatic renal cell carcinoma (mRCC) without any direct comparison between the …
[HTML][HTML] Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis
K Krawczyk, K Śladowska, P Holko… - Frontiers in …, 2023 - frontiersin.org
Objective: This study aimed to compare the safety profile of tyrosine kinase inhibitors (TKIs)
approved for use as monotherapy or combination therapy for the first-line treatment of adult …
approved for use as monotherapy or combination therapy for the first-line treatment of adult …
[HTML][HTML] Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021
Background Renal cell carcinoma (RCC) is one of the most lethal urological malignancies,
and because early-stage RCC is asymptomatic, many patients present metastatic diseases …
and because early-stage RCC is asymptomatic, many patients present metastatic diseases …
[HTML][HTML] Characterization of neuroendocrine regulation-and metabolism-associated molecular features and prognostic indicators with aid to clinical chemotherapy and …
B Zhang, Q Yuan, B Zhang, S Li, Z Wang… - Frontiers in …, 2023 - frontiersin.org
The worldwide prevalence of pancreatic cancer has been rising in recent decades, and its
prognosis has not improved much. The imbalance of substance and energy metabolism in …
prognosis has not improved much. The imbalance of substance and energy metabolism in …
[HTML][HTML] Theranostic applications of glycosaminoglycans in metastatic renal cell carcinoma
SH Hua, M Viera, GW Yip, BH Bay - Cancers, 2022 - mdpi.com
Simple Summary Glycosaminoglycans (GAGs) are a class of carbohydrates that has been
closely associated with cancer progression. GAGs have been implicated in cancer cell …
closely associated with cancer progression. GAGs have been implicated in cancer cell …